Academic Journals Database
Disseminating quality controlled scientific knowledge

Pharmacokinetics of Amikacin after Intravenous Intramuscular and Subcutaneous Administration in German Shepherd Dog

Author(s): Zhenqing Dai | Yuanqing Lin | Yanying Yu | Dongping Zeng | Yongxue Sun

Journal: Journal of Animal and Veterinary Advances
ISSN 1680-5593

Volume: 11;
Issue: 8;
Start page: 1145;
Date: 2012;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Amikacin | German Shepherd dog | pharmacokinetics | LC-MS/MS | plasma injections | China

The purpose of the study was to compare the pharmacokinetics of amikacin in German Shepherd dogs following single intravenous intramuscular and subcutaneous injections. Amikacin was administrated by a randomized three cross-over design after single intravenous (10 mg kg-1) intramuscular (10 mg kg-1) and subcutaneous injections (10 mg kg-1) in 9 healthy German Shepherd dogs. The concentrations of Amikacin in plasma were determined by LC-MS/MS and the concentration-time data were analyzed with 3 p97 program. It’s best to fit the amikacin concentration-time data to two-compartment open model after single i.v. dosing. The main pharmacokinetic parameters were as follows: T1/2β = (1.61±0.07) h, Vc = (0.10±0.01) L kg-1, CL(s) = (0.08±0.01) l kg-1 ·h, AUC = (129.15±6.74) μg mL-1 ·h. A two-compartment model with first order absorption best described the drug concentration-time data after single i.m. and s.c. in healthy dogs. The main pharmacokinetic parameters were as follows: T1/2α = (0.49±0.07) h and (0.64±0.08) h, respectively; T1/2β = (1.40±0.12) h and (1.78±0.15) h, respectively; Tpeak = (0.79±0.09) h and (0.89±0.07) h, respectively; Cmax = (44.59±2.10) μg mL-1 and (31.42±1.39) μg mL-1, respectively; F = (91.3±6.6) and (81.0±5.6)%, respectively.
Why do you need a reservation system?      Affiliate Program